Related Experiment Videos
Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents
M Dohlsten1, G Hedlund, E Akerblom
1Kabi Pharmacia Therapeutics AB, Lund, Sweden.
Abstract:
The bacterial superantigen staphylococcal enterotoxin (SE) A (SEA) directs cytotoxic T lymphocytes (CTLs) expressing particular sequences of the T-cell receptor (TCR) beta chain to lyse tumor cells expressing major histocompatibility complex (MHC) class II molecules, which serve as receptors for SEs. We now report that chemical conjugates of SEA and the colon carcinoma-reactive monoclonal antibodies (mAbs) C215 or C242 mediate T cell-dependent destruction of colon carcinoma cells lacking MHC class II molecules. SEA was covalently linked to the mAbs C215 and C242 via a PEG-based hydrophilic spacer. The C215-SEA conjugate targeted CD4+ as well as CD8+ CTLs to lyse a panel of colon carcinoma cells lacking MHC class II molecules. T-cell recognition of mAb-SEA conjugates was SEA specific, since SEB-selective T-cell lines with potent cytotoxic activity towards Raji cells coated with SEB did not respond to the C215-SEA conjugate. Unconjugated SEA did not induce T-cell lysis of MHC class II- colon carcinoma cells but efficiently directed CTLs against MHC class II+ Raji cells and certain interferon-treated MHC class II+ colon carcinoma cells. These results suggest that SEA-mAb conjugates retain the SEA-related selectivity for certain TCR beta-chain variable region (V beta) sequences but, in contrast to unconjugated SEA, mediate the TCR interaction in a MHC class II-independent manner. The cytotoxic activity mediated by C215-SEA and C242-SEA conjugates was blocked by excess of C215 mAb and C242 mAb, respectively, showing that the specificity in the targeting of mAb-SEA conjugates is defined by the antigen reactivity of the mAb. These results demonstrate that bacterial superantigens may be successfully conjugated to mAb with preserved T cell-activating capacity. The circumvention of MHC class II binding of SEs by conjugation to mAb suggests that such conjugates may find general application as antitumor agents, taking advantage of the extreme T cell-activating potency of superantigens.
Insights
Bacterial superantigens conjugated to monoclonal antibodies (mAbs) enable T-cell destruction of tumor cells lacking MHC class II molecules. This approach circumvents traditional superantigen-dependent targeting for potential new cancer therapies.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Bacterial superantigens like staphylococcal enterotoxin A (SEA) activate T cells to target tumor cells expressing MHC class II.
- This activation is restricted by T-cell receptor (TCR) beta chain sequences and MHC class II expression on target cells.
- Tumor cells often downregulate MHC class II, limiting the efficacy of SEA-mediated tumor cell lysis.
Purpose of the Study:
- To develop novel anti-cancer agents by chemically conjugating SEA to monoclonal antibodies (mAbs).
- To investigate if SEA-mAb conjugates can mediate T-cell dependent tumor cell destruction independently of MHC class II expression.
- To assess the specificity and efficacy of these conjugates in targeting colon carcinoma cells.
Main Methods:
- Covalent linkage of SEA to colon carcinoma-reactive mAbs (C215 or C242) using a PEG-based spacer.
- Testing the cytotoxic activity of SEA-mAb conjugates against colon carcinoma cell lines lacking MHC class II.
- Evaluating T-cell specificity using SEA- and SEB-selective T-cell lines and blocking assays with unconjugated mAbs.
Main Results:
- SEA-mAb conjugates (C215-SEA, C242-SEA) induced T-cell dependent lysis of colon carcinoma cells that lack MHC class II molecules.
- The conjugates retained SEA specificity for TCR V beta sequences but mediated T-cell activation independently of MHC class II.
- Targeting specificity was confirmed by mAb-dependent blocking of cytotoxic activity.
- Unconjugated SEA was ineffective against MHC class II-negative tumor cells, highlighting the advantage of the conjugate approach.
Conclusions:
- Chemical conjugation of SEA to mAbs circumvents the requirement for MHC class II expression on tumor cells.
- SEA-mAb conjugates preserve T-cell activating capacity and specific targeting, offering a promising strategy for cancer immunotherapy.
- This approach leverages the potent T-cell activating properties of superantigens for broader anti-tumor applications.